Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

brentuximab vedotin

(bren-TUK-sih-mab veh-DOH-tin)
A drug used alone or with other drugs to treat adults with certain types of classic Hodgkin lymphoma, cutaneous or systemic anaplastic large cell lymphoma, large B-cell lymphoma, mycosis fungoides, or peripheral T-cell lymphoma, and with other drugs to treat children aged 2 years and older with certain types of classic Hodgkin lymphoma. It is also being studied in the treatment of other types of cancer. Brentuximab vedotin contains a monoclonal antibody that binds to a protein called CD30, which is found on some lymphoma cells. It also contains an anticancer drug, which may help kill cancer cells. Brentuximab vedotin is a type of antibody-drug conjugate. Also called Adcetris and SGN-35.
More Information
Search NCI's Dictionary of Cancer Terms